43 results
8-K
BTAI
BioXcel Therapeutics Inc
22 Apr 24
Regulation FD Disclosure
7:10am
(ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
22 Apr 24
Regulation FD Disclosure
7:10am
with the increased scrutiny relating to environmental, social and governance (ESG) matters ; risks associated with federal, state or foreign health care “fraud … of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated
8-K
EX-99.1
BTAI
BioXcel Therapeutics Inc
10 Apr 24
Regulation FD Disclosure
7:05am
to environmental, social and governance (ESG) matters ; risks associated with federal, state or foreign health care “fraud and abuse” laws ; and its
8-K
BTAI
BioXcel Therapeutics Inc
10 Apr 24
Regulation FD Disclosure
7:05am
) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates
424B5
BTAI
BioXcel Therapeutics Inc
25 Mar 24
Prospectus supplement for primary offering
4:01pm
disorder in adults. IGALMITM is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we … or II disorder in adults. IGALMI is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, we
8-K
EX-99.1
xhbo1955az9
12 Mar 24
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
7:15am
8-K
EX-99.1
mfizf4pd
14 Feb 24
Regulation FD Disclosure
7:00am
424B5
3bs371q8jvy4
8 Feb 24
Prospectus supplement for primary offering
5:27pm
8-K
EX-10.1
2gov8x2ffak9s2eod5
8 Feb 24
Other Events
4:53pm
424B5
e0jbrebt
14 Nov 23
Prospectus supplement for primary offering
8:57am
8-K
EX-99.1
8scrnd6m9h
14 Nov 23
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
flu7v
14 Aug 23
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
7:20am
8-K
EX-99.1
6v4na 7ugqv5
8 May 23
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
8:30am